Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).

Vincenza Conteduca,Daniel Wetterskog,Mansour Taghavi Azar Sharabiani,Anuradha Jayaram,Samanta Salvi,Alessandro Romanel,Cristian Lolli,Valentina Casadio,Giorgia Gurioli,Dino Amadori,Delila Gasi Tandefelt,Anna Wingate,David P. Dearnaley,Francesca Demichelis,Ugo De Giorgi,Enrique Gonzalez-Billalabeitia,Gerhardt Attard

Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).

2017

Vincenza Conteduca
Daniel Wetterskog
Mansour Taghavi Azar Sharabiani
Anuradha Jayaram
Samanta Salvi
Alessandro Romanel
Cristian Lolli
Valentina Casadio
Giorgia Gurioli
Dino Amadori
Delila Gasi Tandefelt
Anna Wingate
David P. Dearnaley
Francesca Demichelis
Ugo De Giorgi
Enrique Gonzalez-Billalabeitia
Gerhardt Attard

5060Background: There is an urgent need to identify biomarkers to guide personalized therapy in CRPC. We aimed to clinically qualify the association of AR status in plasma DNA with worse outcome in...

Keywords:

Androgen receptor
Abiraterone
Pathology
Prostate cancer
Enzalutamide
Castration
Cancer research
Medicine
Oncology
plasma dna
Internal medicine
personalized therapy
castration resistant
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations